FT
EIDX

Fiduciary Trust’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Fiduciary Trust’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,999
Closed -$202K – 588
2020
Q3 		$202K Buy
+3,999
New +$180K ﹤0.01% 534
2020
Q1 		– Sell
-9,000
Closed -$517K – 542
2019
Q4 		$517K Hold
9,000
– – 0.01% 376
2019
Q3 		$324K Hold
9,000
– – 0.01% 435
2019
Q2 		$280K Hold
9,000
– – 0.01% 439
2019
Q1 		$211K Buy
+9,000
New +$144K 0.01% 455

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Fiduciary Trust's EIDX Position: Q4 2020 in Review

Fiduciary Trust sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 3,999 shares — an estimated $202K sold.

Fiduciary Trust first reported a position in EIDX in Q1 2019 and held it in 5 quarters. The position peaked at $517K in Q4 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

  • Fiduciary Trust reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Fiduciary Trust sold 3,999 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $202K.
  • Fiduciary Trust first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
  • Fiduciary Trust's Eidos Therapeutics, Inc. Common Stock position peaked at $517K in Q4 2019.
  • 121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Fiduciary Trust's 13F filing for Q4 2020, filed 26 Jan 2021.